JP2023509354A5 - - Google Patents
Info
- Publication number
- JP2023509354A5 JP2023509354A5 JP2022536924A JP2022536924A JP2023509354A5 JP 2023509354 A5 JP2023509354 A5 JP 2023509354A5 JP 2022536924 A JP2022536924 A JP 2022536924A JP 2022536924 A JP2022536924 A JP 2022536924A JP 2023509354 A5 JP2023509354 A5 JP 2023509354A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- range
- preparation according
- pharmaceutical
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2019000104A CU20190104A7 (es) | 2019-12-17 | 2019-12-17 | Formulación estable del anticuerpo nimotuzumab |
| CUCU-2019-0104 | 2019-12-17 | ||
| PCT/CU2020/050007 WO2021121444A2 (es) | 2019-12-17 | 2020-12-10 | Formulación estable y de alta concentración del anticuerpo nimotuzumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509354A JP2023509354A (ja) | 2023-03-08 |
| JP2023509354A5 true JP2023509354A5 (https=) | 2023-12-12 |
| JP7796646B2 JP7796646B2 (ja) | 2026-01-09 |
Family
ID=76478863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536924A Active JP7796646B2 (ja) | 2019-12-17 | 2020-12-10 | 抗体ニモツズマブの安定で高濃度の製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230018364A1 (https=) |
| EP (1) | EP4079294A2 (https=) |
| JP (1) | JP7796646B2 (https=) |
| KR (1) | KR20220119091A (https=) |
| CN (1) | CN114867468A (https=) |
| AU (1) | AU2020409887B2 (https=) |
| BR (1) | BR112022010488A2 (https=) |
| CA (1) | CA3163630A1 (https=) |
| CO (1) | CO2022009693A2 (https=) |
| CU (1) | CU20190104A7 (https=) |
| MX (1) | MX2022007509A (https=) |
| WO (1) | WO2021121444A2 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2654794A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| PE20150964A1 (es) * | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| EP3541413A2 (en) * | 2016-11-21 | 2019-09-25 | Polpharma Biologics S.A. | Aqueous pharmaceutical formulations |
| CN107898756B (zh) * | 2017-12-22 | 2020-11-20 | 东曜药业有限公司 | 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用 |
-
2019
- 2019-12-17 CU CU2019000104A patent/CU20190104A7/es unknown
-
2020
- 2020-12-10 BR BR112022010488A patent/BR112022010488A2/pt unknown
- 2020-12-10 EP EP20903282.0A patent/EP4079294A2/en active Pending
- 2020-12-10 WO PCT/CU2020/050007 patent/WO2021121444A2/es not_active Ceased
- 2020-12-10 JP JP2022536924A patent/JP7796646B2/ja active Active
- 2020-12-10 CA CA3163630A patent/CA3163630A1/en active Pending
- 2020-12-10 CN CN202080088100.8A patent/CN114867468A/zh active Pending
- 2020-12-10 US US17/786,094 patent/US20230018364A1/en active Pending
- 2020-12-10 MX MX2022007509A patent/MX2022007509A/es unknown
- 2020-12-10 KR KR1020227024674A patent/KR20220119091A/ko active Pending
- 2020-12-10 AU AU2020409887A patent/AU2020409887B2/en active Active
-
2022
- 2022-07-11 CO CONC2022/0009693A patent/CO2022009693A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
| KR20220024915A (ko) | 튜불리신 유사체 대 세포-결합 분자의 접합체의 제형 | |
| TW201806617A (zh) | 穩定之液體醫藥調配物 | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| WO2017055966A1 (en) | Low viscosity antibody compositions | |
| CN114746439A (zh) | 整合蛋白抗体的稳定制剂 | |
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| JP2023509354A5 (https=) | ||
| WO2022151940A1 (zh) | 一种稳定的帕妥珠单抗的药物组合物 | |
| JP6179939B2 (ja) | 高濃度γグロブリン製剤の粘度低下方法 | |
| CN116077650A (zh) | 一种稳定的新冠中和抗体的药物组合物及其应用 | |
| CN113082203B (zh) | 一种免疫抑制剂单克隆抗体的液体制剂 | |
| WO2026018889A1 (ja) | ワクチンアジュバントを含むリポソーム製剤 | |
| JP2023549706A5 (https=) | ||
| JP2024514935A5 (https=) | ||
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| JP2021533149A5 (https=) | ||
| RU2020113092A (ru) | Препараты антител против her2 для подкожного введения | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies |